Anti-adalimumab antibodies in juvenile idiopathic arthritis: Frequent association with loss of response

Scandinavian Journal of Rheumatology

Volumn 44, Issue 5, 2015, Pages 359-362

  Skrabl Baumgartner, A ^a   Erwa, W ^a   Muntean, W ^a   Jahnel, J ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADALIMUMAB ANTIBODY; ANTIBODY; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; IMMUNOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME;

ADALIMUMAB; ADOLESCENT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOMARKERS; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84943246649     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2015.1022213     Document Type: Article

References (14)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007; 369: 767-78.
2. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-20.
3. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010; 38: 82-9.
4. Kosmac M, Avcin T, Toplak N, Simonini G, Cimaz R, Curin Serbec V. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr Res 2011; 69: 243-8.
5. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
6. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72: 1947-55.
7. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
8. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658-66.
9. Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 2012; 64: 2366-74.
10. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007; 27: 269-74.
11. Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T. et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol 2012; 31: 1713-21.
12. van Vollenhoven RF. Switching between biological agents. Clin Exp Rheumatol 2004; 22: S115-21.
13. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010; 12: 217.
14. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012; 71: 1914-15.